Premium
Lower Calcineurin Inhibitor Doses in Older Compared to Younger Kidney Transplant Recipients Yield Similar Troughs
Author(s) -
Jacobson P. A.,
Schladt D.,
Oetting W. S.,
Leduc R.,
Guan W.,
Matas A. J.,
Israni A.
Publication year - 2012
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/j.1600-6143.2012.04232.x
Subject(s) - medicine , calcineurin , tacrolimus , dosing , young adult , kidney transplant , kidney transplantation , prospective cohort study , middle age , transplantation , urology , kidney
The number of older adults undergoing kidney transplantation has increased, yet little is known about calcineurin inhibitor (CNI) metabolism in this group. We studied CNI troughs and doses to determine if there were age‐related differences in metabolism and dose requirements. We studied 348 young (18–34 years), 1831 middle (35–64 years) and 374 older (65–84 years) adult kidney transplant recipients enrolled in a seven‐center prospective study. Troughs were obtained from each patient 2×/week in weeks 1–8 and 2×/month in months 3–6. A multivariable linear‐mixed model examined the effect of age on log dose and weight normalized troughs. Older recipients had higher normalized tacrolimus troughs than middle or young age adults despite receiving doses a median of 1–2 mg/day lower. Age and CYP3A5*1 genotype had the largest effect on tacrolimus troughs. Older recipients also had higher normalized cyclosporine troughs than middle or young adults despite receiving median doses 100 mg/day lower. After normalization for dose and weight, CNI troughs were more than 50% higher in older adults than young adults. These data support age‐related changes in CNI metabolism. Further studies are needed to determine optimal dosing of CNIs in the elderly.